Yusuke Kinugasa

Dr. Yusuke Kinugasa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YKYukihide Kanemitsu
Yukihide Kanemitsu
JMJunki Mizusawa
Junki Mizusawa
YIYoshitaka Inaba
Yoshitaka Inaba
THTetsuya Hamaguchi
Tetsuya Hamaguchi
DSDai Shida
Dai Shida
OGon behalf of the JCOG Colorectal Cancer Study Group
on behalf of the JCOG Colorectal Cancer Study Group
PURPOSE: Adjuvant chemotherapy after hepatectomy is controversial in liver-only metastatic colorectal cancer (CRC). We conducted a randomized controlled trial to examine if adjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) is superior to hepatectomy alone for liver-only metastasis from CRC. PATIENTS AND METHODS: In this phase II or III trial (JCOG0603), patients age 20-75 years with confirmed CRC and an unlimited number of liver metastatic lesions were randomly assigned to hepatectomy alone or 12 courses of adjuvant mFOLFOX6 after hepatectomy. The primary end point of phase III was disease-free survival (DFS) in intention-to-treat analysis. RESULTS: Between March 2007 and January 2019, 300 patients were randomly assigned to hepatectomy alone (149 patients) or hepatectomy followed by chemotherapy (151 patients). At the third interim analysis of phase III with median follow-up of 53.6 months, the trial was terminated early according to the protocol because DFS was significantly longer in patients treated with hepatectomy followed by chemotherapy. With median follow-up of 59.2 months, the updated 5-year DFS was 38.7% (95% CI, 30.4 to 46.8) for hepatectomy alone compared with 49.8% (95% CI, 41.0 to 58.0) for chemotherapy (hazard ratio, 0.67; 95% CI, 0.50 to 0.92; one-sided P = .006). However, the updated 5-year overall survival (OS) was 83.1% (95% CI, 74.9 to 88.9) with hepatectomy alone and 71.2% (95% CI, 61.7 to 78.8) with hepatectomy followed by chemotherapy. In the chemotherapy arm, the most common grade 3 or higher severe adverse event was neutropenia (50% of patients), followed by sensory neuropathy (10%) and allergic reaction (4%). One patient died of unknown cause after three courses of mFOLFOX6 administration. CONCLUSION: DFS did not correlate with OS for liver-only metastatic CRC. Adjuvant chemotherapy with mFOLFOX6 improves DFS among patients treated with hepatectomy for CRC liver metastasis. It remains unclear whether chemotherapy improves OS.

1 March 2021 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SKShin-Ei Kudo
Shin-Ei Kudo
KIKatsuro Ichimasa
Katsuro Ichimasa
BVBenjamin Villard
Benjamin Villard
YMYuichi Mori
Yuichi Mori
MMMasashi Misawa
Masashi Misawa
KMKensaku Mori
Kensaku Mori

4 November 2025 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YKYusuke Kinugasa
Yusuke Kinugasa
KUKay Uehara
Kay Uehara
KYKensei Yamaguchi
Kensei Yamaguchi
YSYutaka Saito
Yutaka Saito
KMKeiko Murofushi
Keiko Murofushi
JRJapanese Society For Cancer Of The Colon And Rectum
Japanese Society For Cancer Of The Colon And Rectum
The number of deaths from colorectal cancer in Japan continues to rise, with over 50,000 deaths recorded in 2018. In the 2024 edition, revisions to all aspects of treatment were undertaken, with corrections and additions made based on knowledge gained since the 2022 version (drug therapy) and the 2019 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer have been prepared to present standard treatment strategies, reduce disparities among institutions, avoid both unnecessary and insufficient treatment, and enhance mutual understanding between healthcare professionals and patients by making these guidelines accessible to the public. These guidelines were developed through consensus by the JSCCR Guideline Committee, following a careful review of evidence retrieved from literature searches and considering the medical insurance system and actual clinical practice in Japan. Therefore, these guidelines serve as a tool for managing colorectal cancer in real-world clinical settings. More specifically, they can be used to support obtaining informed consent from patients and selecting the most appropriate treatment method for each patient. Controversial topics were selected as clinical questions, and recommendations were provided. Each recommendation is accompanied by an evidence classification and a recommendation category, both based on consensus reached by the Guideline Committee members. This article presents the English version of the JSCCR guidelines 2024.

1 February 2014 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
HUHideki Ueno
Hideki Ueno
KHKazuo Hase
Kazuo Hase
YHYojiro Hashiguchi
Yojiro Hashiguchi
HSHideyuki Shimazaki
Hideyuki Shimazaki
MTMasafumi Tanaka
Masafumi Tanaka
KSKenichi Sugihara
Kenichi Sugihara
The study aimed to determine the value of a novel site-specific grading system based on quantifying poorly differentiated clusters (PDC; Grade(PDC)) in colorectal cancer (CRC). A multicenter pathologic review involving 12 institutions was performed on 3243 CRC cases (stage I, 583; II, 1331; III, 1329). Cancer clusters of ≥5 cancer cells and lacking a gland-like structure (PDCs) were counted under a ×20 objective lens in a field containing the maximum clusters. Tumors with <5, 5 to 9, and ≥10 PDCs were classified as grades G1, G2, and G3, respectively. According to Grade(PDC), 1594, 1005, and 644 tumors were classified as G1, G2, and G3 and had 5-year recurrence-free survival rates of 91.6%, 75.4%, and 59.6%, respectively (P<0.0001). Multivariate analysis showed that Grade exerted an influence on prognostic outcome independently of TNM staging; approximately 20% and 46% of stage I and II patients, respectively, were selected by Grade(PDC) as a population whose survival estimate was comparable to or even worse than that of stage III patients. Grade(PDC) surpassed TNM staging in the ability to stratify patients by recurrence-free survival (Akaike information criterion, 2915.6 vs. 2994.0) and had a higher prognostic value than American Joint Committee on Cancer (AJCC) grading (Grade(AJCC)) at all stages. Regarding judgment reproducibility of grading tumors, weighted κ among the 12 institutions was 0.40 for Grade(AJCC) and 0.52 for Grade(PDC). Grade(PDC) has a robust prognostic power and promises to be of sufficient clinical value to merit implementation as a site-specific grading system in CRC.

11 December 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
STShu Tsukihara
Shu Tsukihara
YAYoshimitsu Akiyama
Yoshimitsu Akiyama
SSShu Shimada
Shu Shimada
MHMegumi Hatano
Megumi Hatano
YIYosuke Igarashi
Yosuke Igarashi
Shinji TanakaShinji Tanaka
Shinji Tanaka

2 May 2018 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TYTomohiro Yamaguchi
Tomohiro Yamaguchi
YKYusuke Kinugasa
Yusuke Kinugasa
ASAkio Shiomi
Akio Shiomi
HKHiroyasu Kagawa
Hiroyasu Kagawa
YYYushi Yamakawa
Yushi Yamakawa
HHHitoshi Hino
Hitoshi Hino